PMID- 16445668
OWN - NLM
STAT- MEDLINE
DCOM- 20060517
LR  - 20181030
IS  - 1048-891X (Print)
IS  - 1048-891X (Linking)
VI  - 16
IP  - 1
DP  - 2006 Jan-Feb
TI  - Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a 
      marker for potential molecularly targeted treatment?
PG  - 416-22
AB  - Surgery is the treatment of choice for uterine carcinosarcomas; nevertheless, the 
      poor effect of chemotherapy and radiotherapy represents an insidious problem for 
      patients with metastatic or unresectable disease, and indeed, new therapeutic 
      approaches are clearly required to improve survival of uterine carcinosarcoma 
      patients. The HER-2 oncogene, located on chromosome 17, encodes for a tyrosine 
      kinase growth factor receptor. We analyzed HER-2/neu overexpression by 
      immunohistochemistry in 28 uterine carcinosarcomas. HER-2/neu amplification with 
      fluorescence in situ hybridization (FISH) was tested in positive cases. The 
      expression of HER-2/neu was correlated with disease-free interval and survival 
      (Kaplan-Meier estimates). We observed HER-2/neu overexpression in nine cases 
      (32.1%) and HER-2/neu amplification in all the four HER-2/neu 3+ score positive 
      cases tested by FISH. HER-2/neu expression was not correlated with clinical 
      outcome. Patients with disease limited to the uterus (stages I-II) displayed a 
      significantly better disease-free survival (P= 0.004) and actuarial survival (P= 
      0.01). Demonstration of HER-2/neu overexpression and amplification in uterine 
      carcinosarcoma may represent the first rationale step for further investigations. 
      Hence, the results of this analysis may support the challenge of a new 
      therapeutic approach, which could test the role of anti-HER-2 (trastuzumab) in 
      patients with advanced or metastatic uterine carcinosarcoma.
FAU - Raspollini, M R
AU  - Raspollini MR
AD  - Department of Human Pathology and Oncology, University of Florence, School of 
      Medicine, Viale G.B. Morgagni 85, 50134 Florence, Italy. 
      mariarosaria.raspollini@unifi.it
FAU - Susini, T
AU  - Susini T
FAU - Amunni, G
AU  - Amunni G
FAU - Paglierani, M
AU  - Paglierani M
FAU - Castiglione, F
AU  - Castiglione F
FAU - Garbini, F
AU  - Garbini F
FAU - Carriero, C
AU  - Carriero C
FAU - Scarselli, G
AU  - Scarselli G
FAU - Taddei, G L
AU  - Taddei GL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Biopsy, Needle
MH  - Carcinosarcoma/genetics/mortality/*pathology/*therapy
MH  - Chi-Square Distribution
MH  - Cohort Studies
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2
MH  - Genetic Therapy
MH  - Humans
MH  - Hysterectomy/methods
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Probability
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Survival Rate
MH  - Tissue Culture Techniques
MH  - Uterine Neoplasms/genetics/mortality/*pathology/*therapy
EDAT- 2006/02/01 09:00
MHDA- 2006/05/18 09:00
CRDT- 2006/02/01 09:00
PHST- 2006/02/01 09:00 [pubmed]
PHST- 2006/05/18 09:00 [medline]
PHST- 2006/02/01 09:00 [entrez]
AID - IJG410 [pii]
AID - 10.1111/j.1525-1438.2006.00410.x [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2006 Jan-Feb;16(1):416-22. doi: 
      10.1111/j.1525-1438.2006.00410.x.